MODERNA INC. DL-_0001
Commented by Nico Popp on June 10th, 2025 | 07:20 CEST
Future market – Worth about USD 50 billion: Illumina, Moderna, PanGenomic Health
Medicine is becoming personal. The era of one-size-fits-all drugs is coming to an end. Experts at BCC Research predict that the market for personalized medicine will grow from USD 54.2 billion in 2023 to USD 100.5 billion by 2028. That represents an annual growth rate of 13.2%. Other analysis firms, such as Grand View Research and Market Research Intellect, confirm this promising outlook for investors. All the more reason to take a closer look at Illumina, Moderna, and PanGenomic Health and explore the opportunities they present for investors.
Read
Commented by Stefan Feulner on April 19th, 2023 | 07:30 CEST
Morphosys, Defence Therapeutics, Moderna - The takeover wave keeps rolling
The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions to unmet medical needs. The most recent example is Pfizer's acquisition of Seagen for USD 43 billion. With Big Pharma sitting on filled coffers, this is likely to be just the beginning.
Read
Commented by Stefan Feulner on December 8th, 2022 | 09:25 CET
Core One Labs, BioNxt Solutions, Moderna - Takeover battle in a billion-dollar market
The sharp correction of recent months hit the capital-intensive biotech sector particularly hard. Shares, mainly from the second tier, have, in some cases, had to absorb losses of more than three-quarters of their market value and are trading far below their cash levels. These distortions naturally attract the big players to acquire novel developments at bargain prices.
Read
Commented by Fabian Lorenz on November 3rd, 2022 | 12:01 CET
BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?
BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.
Read
Commented by Carsten Mainitz on September 22nd, 2022 | 10:25 CEST
Moderna, BrainChip Holdings, Infineon - And the winner is?
For many years now, the Boston Consulting Group (BCG) has been selecting the 50 most innovative companies in the world. A few days ago, the hit list was published for the sixteenth time. The top ranks are occupied by Apple, Microsoft, Amazon, Alphabet and Tesla. German companies are only found with Siemens from rank 20. Innovations play an important role for investors because they enable competitive advantages, which sooner or later translates into rising share prices. But global companies are not always the only ones to be considered; it is often lucrative to look at the second tier.
Read
Commented by André Will-Laudien on February 22nd, 2022 | 13:05 CET
BioNTech, Moderna, Valneva, Cardiol Therapeutics: The gold rush is over!
The mild progression of the Omicron variant and the associated massive relaxations of the Corona measures in many countries weighs heavily on the prospects of the vaccine manufacturers. That is because the winter is drawing to a close, clinical shortages are not occurring, and vaccination rates do not want to increase despite massive public campaigns. Meanwhile, even those in power realize that enforcing a general vaccination requirement could become a hot legal ride under the current circumstances. For the biotech sector and vaccine producers, in particular, this is a reason for profit-taking for the time being. Here are a few further ideas.
Read
Commented by Stefan Feulner on January 20th, 2022 | 09:15 CET
Valneva, XPhyto, BioNTech - This is the breakthrough
The shares of vaccine manufacturers are currently experiencing a rollercoaster ride. While BioNTech, Pfizer and Moderna vaccines, based on mRNA technology, continue to reduce their incredible stock market valuation, Valneva, the manufacturer of an inactivated vaccine, has made a brilliant comeback on the stock market floor. The reasons for the good mood were positive data regarding the neutralization of the Omicron variant, which pushed the share up by more than 30% after trading hours.
Read
Commented by Mario Hose on January 12th, 2022 | 10:53 CET
Trading stocks after EMA warning in focus: BioNTech, Johnson + Johnson, Moderna
On Wednesday, the German indices began with a positive sign. The German benchmark index DAX is currently quoted at a level of 16,004 points and thus around 0.04% slightly up. The companies in the second tier can also hold their ground and the MDAX last traded at 34,864 points (+0.26%), TexDAX at 3,644 points and thus 0.60% lower than the previous day. SDAX also loses and last traded at 15,969 points (-0.23%).
Read
Commented by André Will-Laudien on December 21st, 2021 | 13:54 CET
Troilus Gold, Valneva, Moderna, BioNTech - Where will these stocks be in 2022?
The winners in the 2021 investment year have undeniably been the hydrogen, lithium and vaccine stocks. They temporarily gained up to 2,000% but also corrected by more than 50% in some cases. These value developments were not always fundamentally justified. Often the assumption of future achievements was sufficient for a corresponding positive development. In the case of the vaccine manufacturers, the stock market players' fantasies were fulfilled; in the case of hydrogen, this statement was valid at least for a 3-month window at the beginning of the year. Unfortunately, the year was disappointing for most gold explorers, as the precious yellow metal was unable to capitalize on the great uncertainty since the outbreak of the pandemic with a price increase. But this could change in 2022 ad hoc!
Read
Commented by Stefan Feulner on November 19th, 2021 | 12:15 CET
Moderna, Tembo Gold, Nvidia - Running!
The Corona pandemic is currently experiencing its peak in terms of infection numbers in its fourth wave. Thanks to booster shots and the soon to be approved vaccine for children, vaccine manufacturers are profiting. As a result of the torn supply chains and the semiconductor crisis, chip manufacturers are posting record results due to sharply increased prices. Inflation combined with the current low interest rate environment is, in turn, fodder for gold companies. Profit from this cycle.
Read